Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2004

View Archived Issues

First phase I/II data on the efficacy and safety of HuMax-CD20 in follicular lymphoma

TLK-199 shows promise in the treatment of MDS

New phase I data on the antitumor effects and safety of talabostat

Preclinical studies support the use of AQ4N to treat lymphoproliferative diseases

Update on the pharmacokinetics of erlosamide in healthy volunteers

NFkappaB-selective estrogen receptor ligand promising against rheumatoid arthritis

Plasmin-specific inhibitor shows potent antiinvasive and antiangiogenic effects in vitro

Triad Therapeutics sells p38 kinase inhibitor program to Novartis

Specific myosin activator may be useful for treatment of heart failure

Phase II glioblastoma multiforme study for 131I-TM-601

Tapestry advances development of lead oncolytic drugs

Pilot pharmacokinetic study for zolpidem lingual spray formulation

RxGen awarded phase I of fast track SBIR grant for Parkinson's research

Enrollment completed in phase III colonoscopy study of INKP-102

New prostaglandin I2 receptor antagonists in early development at Roche

Boehringer Ingelheim scientists report agents for the treatment of hepatitis C infection

Wyeth researchers develop an antibiotic from Micromonospora

Roche patent covers novel adenosine receptor modulators for Alzheimer's, Parkinson's, etc.

New adenosine receptor antagonists and their use described in Fujisawa patent

New treatments for Parkinson's disease claimed in Schering patent

Enrollment completed in first pivotal study of milnacipran for FMS

European marketing of Alvesco to commence in 2005

Positive findings from Bentley's phase II study of intranasal insulin in diabetics

PHX-1149 scheduled to enter clinic for type 2 diabetes in 2005

Phase IIa study of PA-457 in HIV patients

FTC requests extension for review of MDX-010 collaboration

Aventis spins off Novexel

PEG-Intron available in Japan in combination with Rebetol for HCV

Teikoku Hormone and Grelan Pharmaceutical to merge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...